Opthea (ASX:OPT) is a clinical-stage biopharmaceutical company developing innovative gene therapies to treat a range of ophthalmic diseases, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), geographic atrophy (GA), and Stargardt disease. Opthea's key projects include the development and commercialization of its lead product candidates, OPT-302 and OPT-401. OPT-302 is a novel gene therapy for wet AMD that is currently in Phase 3 clinical trials. OPT-401 is a novel gene therapy for DME that is currently in Phase 2 clinical trials. Opthea is also developing OPT-801, a novel gene therapy for GA, and OPT-900, a novel gene therapy for Stargardt disease, both of which are currently in preclinical development.